# A Study of Single Doses of Frespaciguat (MK-5475) on Pulmonary Vascular Resistance (MK-5475-002)

> **NCT03744637** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 25 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Frespaciguat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03744637
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-18
- **Primary completion:** 2020-12-11
- **Final completion:** 2020-12-11
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03744637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03744637, "A Study of Single Doses of Frespaciguat (MK-5475) on Pulmonary Vascular Resistance (MK-5475-002)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03744637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*